Table 2.
Pathological feature-N | Phosphorylated ERK-1/ERK-2 | P Value* | ||
---|---|---|---|---|
H-score† less than 1 (N = 35) | H-score equal or more than 1 (N = 22) | |||
Tumor grade‡ | 0.34 | |||
Low | 22 | 11 | ||
Intermediate | 5 | 4 | ||
High | 8 | 7 | ||
Intracystic component§ | 0.72 | |||
Yes | 19 | 13 | ||
No | 16 | 9 | ||
Neural invasion | 0.72 | |||
Yes | 7 | 3 | ||
No | 28 | 19 | ||
Necrosis | 0.79 | |||
Yes | 9 | 5 | ||
No | 26 | 17 | ||
Mitosis¶ | 0.36 | |||
Yes | 2 | 3 | ||
No | 33 | 19 | ||
Anaplasia | 0.12 | |||
Yes | 9 | 10 | ||
No | 26 | 12 | ||
Tumor-associated lymphoid proliferation | 0.59 | |||
Yes | 20 | 11 | ||
No | 15 | 11 | ||
Predominance of intermediate cells | 0.08 | |||
Yes | 19 | 17 | ||
No | 16 | 5 |
*, The trend in increasing proportions of phosphorylated ERK-1/ERK-2 immunoreactivity with tumor grade was assessed using the Mann-Whitney U test. For two-by-two comparisons P values were determined using the Fisher’s exact test or the χ2 test.
†, H-score, product of the intensity of staining by the proportion of positive cells.
‡, Tumor grade was established using AFIP criteria.
§, Intracystic component was more than 20% of tumor.
¶, More than 4 mitoses per 1.7 square mm was measured.